G‑Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5) Agonists Reduce the Production of Proinflammatory Cytokines and Stabilize the Alternative Macrophage Phenotype

• Published in: Journal of medicinal chemistry 2014-12, Vol.57 (24), p.10343-10354
• Main Authors: Högenauer, Klemens, Arista, Luca, Schmiedeberg, Niko, Werner, Gudrun, Jaksche, Herbert, Bouhelal, Rochdi, Nguyen, Deborah G, Bhat, B. Ganesh, Raad, Layla, Rauld, Celine, Carballido, José M
• Format: Article
• Language: English
• Subjects: Animals; Anti-Inflammatory Agents - chemistry; Anti-Inflammatory Agents - pharmacology; Calcium - metabolism; Cyclic AMP - metabolism; Enzyme-Linked Immunosorbent Assay; Humans; Indoles - chemistry; Indoles - pharmacology; Inflammation - drug therapy; Inflammation - immunology; Inflammation - metabolism; Interleukin-10 - metabolism; Interleukin-12 - metabolism; Jurkat Cells; Lipopolysaccharides - pharmacology; Macrophages - drug effects; Macrophages - immunology; Macrophages - metabolism; Mice; Mice, Inbred C57BL; Mice, Knockout; Monocytes - drug effects; Monocytes - immunology; Monocytes - metabolism; Niacinamide - analogs & derivatives; Niacinamide - chemistry; Niacinamide - pharmacology; Receptors, G-Protein-Coupled - agonists; Receptors, G-Protein-Coupled - physiology; Tumor Necrosis Factor-alpha - metabolism
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/jm501052c

GPBAR1 (also known as TGR5) is a G-protein-coupled receptor (GPCR) that triggers intracellular signals upon ligation by various bile acids. The receptor has been studied mainly for its function in energy expenditure and glucose homeostasis, and there is little information on the role of GPBAR1 in the context of inflammation. After a high-throughput screening campaign, we identified isonicotinamides exemplified by compound 3 as nonsteroidal GPBAR1 agonists. We optimized this series to potent derivatives that are active on both human and murine GPBAR1. These agonists inhibited the secretion of the proinflammatory cytokines TNF-α and IL-12 but not the antiinflammatory IL-10 in primary human monocytes. These effects translate in vivo, as compound 15 inhibits LPS induced TNF-α and IL-12 release in mice. The response was GPBAR1 dependent, as demonstrated using knockout mice. Furthermore, agonism of GPBAR1 stabilized the phenotype of the alternative, noninflammatory, M2-like type cells during differentiation of monocytes into macrophages. Overall, our results illustrate an important regulatory role for GPBAR1 agonists as controllers of inflammation.